Skip to content

APELLIS PHARMACEUTICALS, INC.: 10-Q filed 2018-07-31

What APELLIS PHARMACEUTICALS, INC. reported in its quarterly report filed 2018-07-31 (fiscal Q2 2018): 25 published measures, 59 facts as tagged in accession 0001564590-18-018096.

This filing

Form
10-Q (quarterly report)
Filed
2018-07-31
Fiscal period
fiscal Q2 2018
Accession
0001564590-18-018096 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All APELLIS PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-30266,817,668USD
At 2017-12-31182,131,456USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-3037,265,562USD
At 2017-12-3133,188,596USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-30229,552,106USD
At 2017-12-31148,942,860USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-06-30253,839,540USD
At 2017-12-31175,643,529USD
At 2017-06-304,939,087USD
At 2016-12-3124,863,488USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-33,334,300USD91
2018-01-01 to 2018-06-30-55,070,606USD181
2017-04-01 to 2017-06-30-12,126,152USD91
2017-01-01 to 2017-06-30-21,176,925USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-53,630,126USD181
2017-01-01 to 2017-06-30-19,924,401USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-06-30131,826,137USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-204,334,259USD
At 2017-12-31-149,263,653USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-06-303,853,715USD181
2017-01-01 to 2017-06-30708,833USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-33,485,442USD91
2018-01-01 to 2018-06-30-54,923,588USD181
2017-04-01 to 2017-06-30-12,132,403USD91
2017-01-01 to 2017-06-30-21,184,896USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-30266,701,518USD
At 2017-12-31182,015,306USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-3010,254,195USD
At 2017-12-316,553,958USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-06-305,133,017USD
At 2017-12-313,663,253USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-04-01 to 2018-06-3027,537,619USD91
2018-01-01 to 2018-06-3044,940,509USD181
2017-04-01 to 2017-06-3010,422,059USD91
2017-01-01 to 2017-06-3017,653,143USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-3056,154,438shares
At 2017-12-3150,334,152shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-06-30433,880,750USD
At 2017-12-31298,201,480USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2018-06-3027,000,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-06-30116,150USD
At 2017-12-31116,150USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-06-305,121,178USD
At 2017-12-312,890,705USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-305,947,823USD91
2018-01-01 to 2018-06-309,983,079USD181
2017-04-01 to 2017-06-301,710,344USD91
2017-01-01 to 2017-06-303,531,753USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-32,867USD91
2018-01-01 to 2018-06-30-64,341USD181
2017-04-01 to 2017-06-30397USD91
2017-01-01 to 2017-06-30-7,995USD181

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2018-04-01 to 2018-06-300USD91
2017-04-01 to 2017-06-300USD91

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2018-04-01 to 2018-06-300USD91
2017-04-01 to 2017-06-300USD91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-06-30131,325,027USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-06-301,469,764USD181
2017-01-01 to 2017-06-3057,186USD181

Inspect the source

Entity
APELLIS PHARMACEUTICALS, INC. / CIK 0001492422
Captured
2026-09-21T17:19:23.869Z
SEC response SHA-256
d855a4e81b3da8707e343214abe406f3014a2ed6d4ac72156c893608477710a5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001492422.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))